v3.26.1
Stockholders' Equity - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2026
Aug. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Feb. 27, 2026
Apr. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award                
Outstanding options that are exercisable (in shares) 1,100,000   1,100,000   1,100,000      
Outstanding options that are exercisable, weighted average exercise price (in USD per share) $ 78   $ 78   $ 78      
Employee Stock Purchase Plan                
Repurchase of common stock         $ 60,000,000 $ 0    
Common Stock                
Employee Stock Purchase Plan                
Repurchase of common stock $ 60,000,000 $ 15,000,000            
Stock repurchased during period (in shares) 228,859 102,034            
Shares acquired, average cost per share $ 262.17 $ 147.01            
April 2023 Repurchase Agreement                
Employee Stock Purchase Plan                
Authorized stock repurchase amount               $ 50,000,000
Stock repurchased during period, value     $ 0 $ 0 $ 0 $ 0    
At-the Market Equity Offering                
Employee Stock Purchase Plan                
Sale of stock, authorized offering amount             $ 100,000,000  
Sale of common stock (in shares)         0      
Amended ESPP                
Employee Stock Purchase Plan                
Share purchase price as percent of market price (as a percent)         85.00%      
Shares available for future purchases (in shares)         17,424      
Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan                
Share-based Compensation Arrangement by Share-based Payment Award                
Number of shares of common stock available (in shares) 600,000